Rurality weakens the positive association between the COVID-19 pandemic and substance use treatment involving medications for opioid use disorder. [PDF]
Lofaro RJ +3 more
europepmc +1 more source
Geographic differences in buprenorphine and methadone prescribing for surgical patients with opioid use disorder. [PDF]
Coates CP +4 more
europepmc +1 more source
State Laws Banning Prior Authorization For Medications For Opioid Use Disorder Increased Substantially, 2015-23. [PDF]
Hu JC +5 more
europepmc +1 more source
Access to medications for opioid use disorder among primary care patients with homeless experience in the Department of Veterans Affairs. [PDF]
Jones AL +10 more
europepmc +1 more source
Pre-exposure prophylaxis (PrEP) and medications for opioid use disorder for persons who inject drugs: the CHORUS + randomized controlled trial study protocol. [PDF]
Miller SE +14 more
europepmc +1 more source
Systemic Inertia in Addiction Care: Institutional Hesitancy and Ethical Barriers to Buprenorphine Initiation. [PDF]
Ramírez-Rivera E +3 more
europepmc +1 more source
"They should be like penicillin": barriers to the integration of medications for opioid use disorder in specialty treatment programs. [PDF]
Desai IK +7 more
europepmc +1 more source
State Proposed Strategies to Expand Access to Medications for Opioid Use Disorder. [PDF]
Baron A +4 more
europepmc +1 more source
Seven Steps for Emergency Physicians to Dismantle Access Barriers and Build Equitable Care Systems. [PDF]
Gonzalez AM, Keating E, Moulin A.
europepmc +1 more source
Buprenorphine Treatment for Opioid Use Disorder in Non-Addiction Specialty Settings.
Huebler S +6 more
europepmc +1 more source

